Merck & Co., Inc. (NYSE:MRK), a leading global healthcare company, continues to navigate the competitive landscape of the pharmaceutical industry against giants like Pfizer and Johnson & Johnson. On March 12, 2026, Wells Fargo reaffirmed its "Overweight" rating on Merck, with an optimistic price target adjustment to $150, as reported by StreetInsider.
On the latest trading day, Merck's stock demonstrated resilience, closing at $117.11, which represents a 1.14% increase from its previous close. This performance surpassed the gains of major indexes, including the S&P 500, the Dow, and the Nasdaq. Despite a prior 5.04% decline, investors are closely monitoring Merck's financial health, especially with the upcoming earnings report on April 30, 2026. Analysts predict an EPS of -$0.57, marking a significant 125.68% decline year-over-year, while revenue is expected to see a 3.09% increase to $16.01 billion.
Merck faces hurdles with its Gardasil vaccine, experiencing a 39% sales drop in 2025, largely due to diminished demand in China amid economic challenges. This downturn has affected Merck's partnership with Zhifei, leading to halted Gardasil shipments to the region. The company also reports reduced Gardasil demand in Japan and declines in other vaccine sales in 2025. With no anticipated rebound in Gardasil sales for 2026, Merck's revenue stream may continue to be under pressure. Despite these challenges, Merck's market capitalization remains robust at approximately $287.34 billion, with a trading volume of 4,870,098 shares on the NYSE.
